BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC - BeiGene Australia

Australia
- Australia
- Canada EN|FR
- China
- Germany
- Global
- Spain
- US

https://ir.beigene.com/news-details/?id=09127f95-fd94-4a1b-b215-3e356e5fcfd9

You will be redirected to

Click the link above to continue or CANCEL